Orekhova S B, Botvin'ev O K, Romantsov M G
Antibiot Khimioter. 2009;54(5-6):48-53.
The clinical and laboratory efficacy of the treatment of children with pyelonephritis with addition of cycloferon, an inductor of early interferon of types 1 and 2, to the main therapy was studied. The mechanism of the cycloferon action was described. The clinical and laboratory remission within a year was observed in 64.3% of the patients treated with addition of cycloferon vs. 47.1% of the patients under the main therapy without the cycloferon addition. The number of the relapses lowered to 7.1% vs. 20.6% of the episodes in the control group. The minimal risk of the disease exacerbation (0.37) in the patients treated with cycloferon and the relative risk of the unfavourable outcomes among the patients under the therapy with addition of cycloferon (0.5967< or =1) were determined.
研究了在主要治疗基础上加用环磷酰胺（1型和2型早期干扰素诱导剂）治疗儿童肾盂肾炎的临床和实验室疗效。描述了环磷酰胺的作用机制。加用环磷酰胺治疗的患者中，64.3%在一年内实现临床和实验室缓解，而主要治疗未加环磷酰胺的患者中这一比例为47.1%。复发次数降至7.1%，而对照组为20.6%。确定了接受环磷酰胺治疗的患者疾病加重的最小风险（0.37）以及加用环磷酰胺治疗的患者出现不良结局的相对风险（0.5967≤1）。
